GeoVax Q2 net loss narrows 17.56% to $4.43 million; revenue turns to no revenue

• GeoVax posted a Q2 net loss of $4.43 million, narrowing from a year earlier as operating loss improved to $4.44 million.
• Revenue fell to no revenue from government contract; R&D expense dropped 34.2% to $3.11 million, G&A slid 13.7% to $1.33 million.
• Six-month net loss narrowed to $9.69 million; operating cash outflow improved to $7.2 million, while financing inflows totaled $7.25 million.
• Cash and cash equivalents were $3.14 million at June 30; management expects funding to last into September 2026, citing going-concern uncertainty.
• Pipeline focus shifted to GEO-MVA and Gedeptin; GEO-MVA Phase 3 start is expected in late 2026, GEO-CM04S1 COVID-19 work was discontinued.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-024523), on July 27, 2026, and is solely responsible for the information contained therein.